文献速递药物相互作用药物不良反应与药物警戒

过去三十年未进入癫痫市场的抗发作药物:临床开发失败因素评估

Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades.
PubMed 文献 · Drugs · 2026-03-01

该研究回顾了自1992年起EILAT会议上报道但未进入抗发作药物(ASM)市场的化合物,限定于针对常见癫痫的临床在研药物。56个化合物中15个上市、11个仍在开发、30个终止癫痫开发。终止多发生于1期或2期,最常见原因为缺乏疗效,药代动力学不佳也常见。

要点

  • 56个在研抗发作药物中30个终止癫痫开发,多发生在1期或2期。
  • 终止最常见原因为缺乏疗效,药代动力学不佳(如半衰期短、药物相互作用潜力高)也常见。
  • 部分化合物因优先开发其他神经或精神适应症而放弃癫痫。

核心结论

  • 30个针对常见癫痫的在研化合物终止了癫痫开发,最常见原因是缺乏疗效,药代动力学不佳也是早期终止的常见原因。

研究设计与样本

  • 回顾性分析自1992年起每两年一次的EILAT新抗癫痫药物会议上公开报道的、针对常见癫痫的临床在研化合物。
  • 共纳入56个化合物,其中15个已上市、11个仍在开发、30个终止癫痫开发。

主要发现

  • 30个终止开发的化合物包括atimepazole、beprodone、cannabidivarin等。
  • 大多数终止发生在1期或2期临床试验阶段。
  • 药代动力学性质不佳(如半衰期短或药物相互作用潜力高)是早期终止的常见可能原因。
  • 总体最常见的终止原因是缺乏疗效,部分可能与试验设计欠佳有关。
  • 对许多化合物,临床前数据提示疗效不足不太可能主要由作用机制解释。

临床怎么用

  • 开发抗发作药物时应重视药代动力学优化,以降低早期终止风险。
  • 临床试验设计应充分,以避免因设计欠佳导致疗效被低估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The EILAT Conferences on New Antiepileptic Drugs (AEDs), which have taken place biennially since 1992, have traditionally offered a forum for stakeholders from industry and academia to present updates on potential antiseizure medications (ASMs) in development. We reviewed publicly accessible data on compounds that were presented at EILAT conferences over this period but failed to reach the ASM market. The overarching aim was to determine the most likely reason(s) for terminating development and to provide potentially useful clues to improve the efficiency of ASM development in the future. We restricted our analysis to investigational compounds in clinical development that targeted common epilepsies. Of 56 such compounds, 15 reached the ASM market, 11 are still in development, and 30 had their development for epilepsy indications terminated. Compounds whose development was terminated include atimepazole, beprodone, cannabidivarin, carabersat, conantokin-G, dezinamide, elpetrigine, flunarizine, fluorofelbamate, ICA-105665, isovaleramide, JNJ-40411813, losigamone, naluzotan, padsevonil, pitolisant, ralitoline, remacemide, safinamide, soretolide, talampanel, tonabersat, T2000, T2007, valnoctamide, valrocemide, VX-765, zandatrigine, zuranolone, and 534U87. For most of these compounds, termination of development occurred during phase 1 or phase 2. Unfavorable pharmacokinetic properties, such as short half-life or high drug-drug interaction potential, were a common likely cause of early termination. Overall, the most common reason for terminating clinical development was lack of efficacy, possibly related, at least in some cases, to use of suboptimal trial designs. Review of preclinical data suggested that, for many compounds, suboptimal clinical efficacy was unlikely to be primarily explained by their mechanism of action. In some instances, failure to pursue an epilepsy indication could be explained by prioritization of development for other neurological or psychiatric conditions. This may reflect the perception of the drug market for common epilepsies being relatively crowded, and only attractive for compounds with outstanding safety or efficacy advantages over existing medications.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Bialer M, Perucca E. Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades. Drugs. 2026. PMID: 41764707. doi:10.1007/s40265-026-02297-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。